

NCCN Neuroendocrine Tumors Guidelines V.1.2011 – Update Teleconference – 04/04/11

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
<p>PancNET-5 Internal request: Institutional Review comment to modify the category designation for sunitinib.</p> <p>External request: Submission from Pfizer Oncology to amend the category recommendation for sunitinib.</p>	<p>Based upon the published reference and panel consensus supporting the recommendation of sunitinib in treatment of pancreatic neuroendocrine tumors, the category designation changed from a 2B to category 2A.</p>	<p>Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501-513. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21306237</p>	15	0	0
<p>PancNET-5 Internal request: Institutional Review comment to modify the category designation for everolimus.</p> <p>External request: Submission from Novartis Oncology to amend the category recommendation for everolimus.</p>	<p>Based upon the published reference and panel consensus supporting the recommendation of everolimus in treatment of pancreatic neuroendocrine tumors, the category designation changed from a 2B to category 2A.</p>	<p>Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21306238.</p>	14	0	1